

Special Issue

From Drug Carriers to Vaccine Adjuvants in Malaria

Message from the Guest Editors

Despite the undeniable importance of malaria elimination on the global research agenda, current vaccines in development do not offer prospects of complete protection, and the available front-line drugs are rapidly losing efficacy, with resistance already evolved to the first-line drug artemisinin. As a result, since 2014 the malaria incidence and mortality decline have stalled. Thus, alternative strategies working through radically new mechanisms are urgently needed. Because malaria pathophysiology is so complex, and the disease is so widespread, it is generally accepted that to achieve eradication a combination of weapons will be needed. These include the improvement of existing approaches and the development of new ones, with drug therapy and vaccination remaining the mainstays of treatment and prevention, and pharmaceutical nanotechnology being a potentially essential tool in the future fight against malaria. Encapsulation of drugs in targeted nanovectors is a rapidly growing area with clear applicability to infectious disease treatment, and malaria vaccine adjuvants based on antigen binding to nanoparticles will be an essential asset for future prophylactic strategies.

Guest Editors

Prof. Dr. Xavier Fernàndez-Busquets

Barcelona Institute for Global Health (ISGlobal), and Institute for Bioengineering of Catalonia (IBEC), Centre Esther Koplowitz, Planta 1, ISGlobal, Rosselló 149-153, ES08036 Barcelona, Spain

Dr. Livia Neves Borgheti-Cardoso

Barcelona Institute for Global Health (ISGlobal), and Institute for Bioengineering of Catalonia (IBEC), Centre Esther Koplowitz, planta 1, ISGlobal, Rosselló 149-153, ES08036 Barcelona, Spain

Deadline for manuscript submissions

closed (29 June 2019)



Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



mdpi.com/si/20552

Pharmaceutics
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceutics@mdpi.com

[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)





Pharmaceutics

an Open Access Journal
by MDPI

Impact Factor 5.5
CiteScore 10.0
Indexed in PubMed



[mdpi.com/journal/
pharmaceutics](https://mdpi.com/journal/pharmaceutics)



About the Journal

Message from the Editor-in-Chief

Pharmaceutics (ISSN 1999-4923) is an online open access journal on the science and technology of pharmaceutics and biopharmaceutics. The scientific community, the wider community and the general public have unlimited and free access to the content as soon as a paper is published; this open access to your research ensures your findings are shared with the widest possible audience. Please consider publishing your impressive work in this high quality journal. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Prof. Dr. Patrick J. Sinko
Department of Pharmaceutics, Ernest Mario School of Pharmacy,
Rutgers University, Piscataway, NJ 08854, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1
(Pharmaceutical Science)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 14.9 days after submission; acceptance to publication is undertaken in 3.3 days (median values for papers published in this journal in the first half of 2025).